Latest MCRPC Stories
Approval based on improved overall survival, delayed time to radiographic progression and an overall positive risk-benefit profile MARKHAM, ON, April 16, 2015 /CNW/ - Astellas
HORSHAM, Pa., March 30, 2015 /PRNewswire/ -- The U.S.
TOKYO and SAN FRANCISCO, March 24, 2015 /PRNewswire/ -- Astellas Pharma Inc. (Tokyo: 4503) and Medivation, Inc.
Circulating tumor cell analysis provides comprehensive information from a real-time liquid biopsy that could help guide treatments for metastatic prostate cancers and bladder cancers SAN
Mediaplanet announces distribution of its second cross-platform edition of Prostate Cancer, raising awareness and providing readers with
While Xtandi Will Dominate the Overall Market, Emerging Hormonal Therapies Will Also Succeed in Capturing Significant Sales, According to Findings from Decision Resources Group BURLINGTON,
Final data after 49-month follow-up analysis in chemotherapy-naïve men with metastatic castration-resistant prostate cancer presented at European Society for Medical Oncology (ESMO) 2014 Congress
Final analysis of Phase 3 COU-AA-302 study presented at the European Society for Medical Oncology (ESMO) 2014 Congress HORSHAM, Pa., Sept.
Phase 2 study data presented at the 50th annual meeting of the American Society of Clinical Oncology HORSHAM, Pa., June 2, 2014 /PRNewswire/ -- Abiraterone acetate (ZYTIGA(®)) plus
- Research in hematological malignancies features: ibrutinib (IMBRUVICA®), siltuximab (SYLVANT(TM)) and daratumumab; research in solid tumors features: abiraterone acetate (ZYTIGA®), ARN-509, trabectedin